Researchers from Chalmers University of Technology, Sweden have developed Artificial Intelligence that is capable of generating novel, functionally active proteins. The research represents a significant breakthrough in the field of synthetic protein development. “What we are now able to demonstrate offers fantastic potential for a number of future applications, such as faster and more cost-efficient development […]
Axol Bioscience, an established provider of iPSC-derived cells, media, and characterization services, has merged with CENSO Biotechnologies, a cell biology CRO with focused expertise in iPSC-related technologies. The new entity will become a leading provider of product and service solutions in the iPSC-based neuroscience, immune cell, and cardiac modeling for drug discovery and screening markets. […]
Albumedix, a Nottingham, UK-based biotech company and world leader in recombinant human albumin (rAlb), will collaborate with the Cell and Gene Therapy Catapult (CGT Catapult) to investigate the use of Albumedix’s proprietary albumin-based solutions for advanced therapy applications, including viral vectors manufacturing.
NovalGen, a biopharmaceutical company developing breakthrough cancer therapies and HALIX B.V., a contract development and manufacturing organisation, have agreed a strategic partnership wherein HALIX will manufacture clinical supplies for NovalGen’s therapies.
WuXi AppTec, a Shanghai, China-headquartered global provider of R&D- and manufacturingenabling services in the pharmaceutical, biotechnology and medical device industries, has acquired OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy technologies. This acquisition enables WuXi AppTec to offer its customers end-to-end support in the creation and […]
La Jolla Institute for Immunology (LJI), a leading research organization focussed on studying the immune system has signed a licensing agreement with Leinco Technologies, a premier developer and manufacturer of leading-edge recombinant proteins, antibodies, and conjugates. Leinco also provides custom manufacturing services to the diagnostic and biopharmaceutical industries to leverage proprietary COVID-19 antibodies developed at […]
UPM Biomedicals will collaborate with bioconvergence company CELLINK to bring together UPM’s expertise for producing non-animal derived, nanocellulose biomaterials with CELLINK’s years of experience in method development for 3D bioprinting, offering new ground-breaking solutions to this growing life sciences market.
Avacta Group, the developer of cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms, has entered into a license agreement with Biokit, a Werfen Company, to incorporate Affimer reagents into a Biokit in-vitro diagnostic (IVD) product.
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
